Third-line chemotherapy in metastatic breast cancer: A retrospective institutional assessment about clinical outcomes.

Abstract

e17538 Background: Third-line chemotherapy in metastatic breast cancer (MBC) has been evaluated in phase II trials, but there were no prospective randomized studies showing clear benefit forward third-line chemotherapy. However, some patients increased their performance and quality of life despite short survival and low response rate. We analyzed the… (More)

Topics

Cite this paper

@article{Crcano2009ThirdlineCI, title={Third-line chemotherapy in metastatic breast cancer: A retrospective institutional assessment about clinical outcomes.}, author={Flavio Mavignier C{\'a}rcano and Maria de F{\'a}tima Dias Gaui and Luciana P Branco}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2009}, volume={27 15_suppl}, pages={e17538} }